Ryan Singhi, MD
Endocrinology, Diabetes & Metabolism · Fort Mill, SCNPI 1568882009
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,271 of the $9,268 with a category attached, or 89.2%. It is spread thinly across 47 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,888 and has fallen 93.0% since, to $202 in 2025.
Across 403 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$915
- Lilly USA, LLC$625
- Sanofi-aventis U.S. LLC$592
- AstraZeneca$545
- Boehringer Ingelheim$470
- plus $5K from 41 others
What the payments were for
- Travel & lodging$90110%
- Food & beverage$8,27189%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$901
- iLet Bionic Pancreas$377
- PROCLAIM$267
- Inspire$139
- SOLIQUA 100/33$125
- AFREZZA$125
- FARXIGA$113
- TEPEZZA$106
- MYCAPSSA$101
- JARDIANCE$100
How this compares
$9,268 in reported general payments places this provider in the 70th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 411 | $530,559 |
| KorlymMifepristone | 13 | $262,210 |
| JardianceEmpagliflozin | 163 | $189,930 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 76 | $145,021 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 158 | $132,585 |
| TrulicityDulaglutide | 85 | $113,965 |
| FarxigaDapagliflozin Propanediol | 92 | $83,435 |
| MounjaroTirzepatide | 36 | $45,567 |
| JanuviaSitagliptin Phosphate | 38 | $43,649 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $40,262 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $32,604 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $31,115 |
| TradjentaLinagliptin | 30 | $28,277 |
| Novolog FlexpenInsulin Aspart | 81 | $22,846 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $22,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $391 | $544,221425 claims |
| Corcept TherapeuticsKorlym | $451 | $262,21013 claims |
| Boehringer IngelheimJardiance, Tradjenta | $470 | $218,207193 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $625 | $163,869143 claims |
| AstraZenecaFarxiga | $545 | $83,43592 claims |
| MerckJanuvia, Janumet | $174 | $50,69051 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $592 | $32,60424 claims |
| AbbVieSynthroid | $177 | $8,749120 claims |
| Cequr CorporationCequr Simplicity | $136 | $8,07118 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $328 | $4,883341 claims |
| IBSA Pharma Inc.Tirosint | $97 | $2,40312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Fort Mill
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
- Beatrice HullCharleston$214K
- Joseph MathewsSummerville$168K
- Brittany HendersonMount Pleasant$157K
- Zouhair BibiConway$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.